跳至主要内容
临床试验/NCT00932477
NCT00932477已完成不适用

Safety and Tolerability of Artificial Tears in Dry Eye Subjects

Allergan0 个研究点目标入组 47 人开始时间: 2009年8月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
Allergan
入组人数
47
主要终点
Tolerability Questionnaire Mean Scores at 1 Week

研究概览

简要总结

The safety and tolerability of two new artificial tears will be compared to a currently-available artificial tear in subjects with dry eye. Each subject will receive all three products in a randomly assigned order. The subject will use one product at a time for a duration of one week before switching to the next assigned product.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Mild, moderate or severe symptoms of dry eye

排除标准

  • Uncontrolled systemic disease
  • Contact lens wear
  • Participation in another clinical study

研究组 & 干预措施

Glycerin and Polysorbate 80 based artificial tear

Active Comparator

Glycerin and Polysorbate 80 based artificial tear

干预措施: Glycerin and Polysorbate 80 based artificial tear (Drug)

结局指标

主要结局

Tolerability Questionnaire Mean Scores at 1 Week

时间窗: 1 Week

Tolerability Questionnaire mean scores at 1 week. The Tolerability Questionnaire includes 8 tolerability questions on selected performance measures. All questions are scored based on continuous visual analog scale from 0-100. The first 4 questions presented measure increasing tolerability where 0=worst and 100=best. The second set of 4 questions presented measure decreasing tolerability where 0=best and 100=worst.

次要结局

  • Number of Patients With at Least One Severity Grade Increase in Biomicroscopy Findings at 1 Week(1 Week)
  • Best-Corrected Visual Acuity (BCVA) Status at 1 Week(1 Week)
  • The Number of Ophthalmic Adverse Events at 1 Week(1 Week)

研究者

发起方
Allergan
申办方类型
Industry
责任方
Sponsor

相似试验